Current Clinical Trial

Phase III Study

For information on the Company’s ongoing clinical trial: MAVIS – A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence, please see

Note:  Polynoma does not presently offer an expanded access program for seviprotimut-L, nor does it plan to in the immediate future.  We are working diligently to accelerate the generation of data from the patients currently enrolled in the MAVIS clinical trial to enable the availability of seviprotimut-L in the U.S. as early as possible – this will make the therapy available to the broadest number of patients in need.